Fluvoxamine: An Overview
Fluvoxamine is an antidepressant medication that is most commonly used to treat obsessive-compulsive disorder (OCD). It belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRIs). Other medications in this class include sertraline, fluoxetine, paroxetine, and citalopram. Fluvoxamine is available in the form of tablets, capsules, extended-release tablets, and oral solutions. It is also used to treat various other conditions such as depression, anxiety, panic disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD).
Fluvoxamine works by blocking the reuptake of the neurotransmitter serotonin. This increases the amount of serotonin available in the brain, which helps to improve mood and reduce anxiety. It is thought to work by modulating the activity of certain pathways in the brain.
Fluvoxamine is generally well-tolerated, but it can cause some side effects. Common side effects include nausea, vomiting, dizziness, headache, drowsiness, insomnia, dry mouth, diarrhea, constipation, and sweating. More serious side effects include increased risk of bleeding, liver damage, and serotonin syndrome. People who are taking fluvoxamine should be monitored for any changes in their mental state and should not stop taking the medication suddenly.
Fluvoxamine is generally safe and effective when used as directed. However, it is important to discuss any potential risks or side effects with a healthcare provider before starting this medication.
References
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
Gartlehner, G., Gaynes, B. N., Hansen, R. A., Thieda, P., DeVeaugh-Geiss, A. M., Krebs, E. E., … & Lohr, K. N. (2011). Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians. Annals of Internal Medicine, 155(11), 772-783.
Lam, R. W., & Kennedy, S. H. (2008). Efficacy of antidepressants: A re-examination. Canadian Journal of Psychiatry, 53(5), 315-324.
National Institute for Health and Care Excellence. (2018). Obsessive-compulsive disorder: Core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. NICE Clinical Guidelines, (CG31). Retrieved from https://www.nice.org.uk/guidance/cg31
Saulnier, C. A., & Geller, D. A. (2009). Fluvoxamine. American Family Physician, 79(4), 317-320.